Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957897 | 1.00 | KDM4E (0.59) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL7378524 | 0.83 | KDM4E (0.73) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL29953525 | 0.82 | LCK (0.58) | KDM4EALDH1A1HSD17B10HPGDHTT | |
| SCHEMBL7466908 | 0.79 | KDM4E (0.68) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL6582728 | 0.79 | KDM4E (0.67) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL28707342 | 0.79 | GAA (0.64) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL666491 | 0.77 | GAA (0.49) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL23525842 | 0.76 | KDM4E (0.63) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL28719929 | 0.76 | KDM4E (0.63) | KDM4EPOLBALDH1A1GAAHSD17B10 | |
| SCHEMBL8980590 | 0.76 | HTT (0.68) | KDM4EPOLBALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| EP-3538529-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018087389-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | IKBKB, NFKBIA, IKBKE | KDM4E 2954/4885POLB 1016/4885ALDH1A1 3837/4885 |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | IKBKB, NFKBIA, IKBKE | KDM4E 2948/4885POLB 691/4885ALDH1A1 3972/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | KDM4E 1872/4885POLB 2583/4885ALDH1A1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.